Journey Medical Corporation (DERM)

Market Cap	186.56M -2.2%
Revenue (ttm)	68.18M +20.9%
Net Income	-6.10M
EPS	-0.23
Shares Out	28.22M
PE Ratio	n/a
Forward PE	33.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	126,128
Open	6.83
Previous Close	6.72
Day's Range	6.47 - 6.88
52-Week Range	4.31 - 9.56
Beta	1.11
Analysts	Strong Buy
Price Target	13.75 (+108.02%)
Est. Earnings	Nov 11, 2026

About DERM

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to se...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Nov 12, 2021
• Employees: 58
• Stock Exchange: Nasdaq
• Ticker Symbol: DERM
• Website: https://journeymedicalcorp.com

Financial Performance

In 2025, Journey Medical's revenue was $61.86 million, an increase of 10.20% compared to the previous year's $56.13 million. Losses were -$11.43 million, -22.09% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for DERM stock is "Strong Buy." The 12-month stock price target is $13.75, which is an increase of 108.02% from the latest price.

Price Target

$13.75

(108.02% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 3, 2026

Data Sources Report a data error